The homeodomain transcription factor encoded by the pancreatic and duodenal homeobox gene-1 (I p f -1) is essential for pancreatic ontogenesis. Whether Ipf-1 is also involved in the neogenesis of -cells in the adult pancreas is unknown. We examined whether Ipf-1 is expressed in adult human pancreatic ducts, which are thought to generate new -cells. In tissue sections, virtually all duct cells were immunopositive for Ipf-1, as were the islet -cells but not the acinar cells. After isolation and culture, both duct and islet cell preparations contained the Ipf-1 immunoreactive proteins p42 and p45 (42 and 45 kDa, respectively) in similar proportions, but the expression levels were twofold lower in duct cells. After 4 h of labeling, the endocrine cells exhibited a sevenfold higher phosphorylation of p42 than the duct cells, whereas p45 was phosphorylated only in endocrine cells. Homeobox binding transcription factor complexes with Ipf-1 in duct cells differed from those in endocrine cells in terms of gel mobility, sequence specificity, and a ff i n i t y. The observed similarities in Ipf-1 expression by adult human pancreatic duct cells and endocrine cells may reflect their common ontogenic origin, whereas the d i fferences in Ipf-1 phosphorylation and complex formation may correlate with their divergent differentiation. Diabetes 49:571-579, 2000 T he mammalian pancreas is an exocrine gland with dispersed endocrine units. It mainly consists of acinar cells that produce digestive enzymes. The exocrine ducts are lined by epithelial cells that secrete large amounts of a bicarbonate-rich fluid. The pancreas develops by progressive branching of duct-like evaginations from the gut epithelium (1,2). Both its endocrine and exocrine components are formed from as-yet-unidentified precursor cells that are assumed to reside in the ductlike structures (3,4). Cellular commitment to a pancreatic fate is characterized by expression of the homeodomain transcription factor encoded by the pancreatic and duodenal homeobox gene-1 (I p f -1) (5-7), which allows growth and differentiation during pancreas development (8-11). Ipf-1 also plays a role in maintaining the phenotype of differentiated -cells (12). The transactivating potential of Ipf-1 is modulated by glucose-induced phosphorylation, which appears to i n fluence its DNA binding potential (13-16). Ipf-1 binds to A elements that are homeodomain binding sites, of which the A3 element is a glucose response element in the human insulin gene promoter (17).
T
he mammalian pancreas is an exocrine gland with dispersed endocrine units. It mainly consists of acinar cells that produce digestive enzymes. The exocrine ducts are lined by epithelial cells that secrete large amounts of a bicarbonate-rich fluid. The pancreas develops by progressive branching of duct-like evaginations from the gut epithelium (1,2). Both its endocrine and exocrine components are formed from as-yet-unidentified precursor cells that are assumed to reside in the ductlike structures (3, 4) . Cellular commitment to a pancreatic fate is characterized by expression of the homeodomain transcription factor encoded by the pancreatic and duodenal homeobox gene-1 (I p f -1) (5-7), which allows growth and differentiation during pancreas development (8-11). Ipf-1 also plays a role in maintaining the phenotype of differentiated -cells (12). The transactivating potential of Ipf-1 is modulated by glucose-induced phosphorylation, which appears to i n fluence its DNA binding potential (13) (14) (15) (16) . Ipf-1 binds to A elements that are homeodomain binding sites, of which the A3 element is a glucose response element in the human insulin gene promoter (17) .
In the rodent embryonic pancreas, Ipf-1 is expressed permanently in the endocrine cells and transiently in most exocrine cells (18) . At the end of gestation, Ipf-1 becomes restricted to -cells and to small subsets of other endocrine cell types (18). In the adult rodent pancreas, Ipf-1 expression can be transiently induced in duct cells after 90% pancreat e c t o m y, which is compatible with a role of this protein in pancreas regeneration (19) . Because normal adult pancreas may also generate new -cells from precursor cells located among the duct cells (4,20), we examined Ipf-1 expression in the adult human exocrine pancreas. After the identific ation of Ipf-1 expression in adult human duct cells, we compared its expression level and phosphorylation status as well as the Ipf-1-containing DNA binding protein complexes in duct and islet cells.
RESEARCH DESIGN AND METHODS
Cell isolation, culture, and metabolic labeling. Adult human pancreases from heart-beating cadaveric nondiabetic donors were procured by European hospitals affiliated with the Eurotransplant Foundation (Leiden, the Netherlands) and with -Cell Transplant, a multicenter program involving -cell transplantation in t y p e 1 diabetic patients. The range of donor ages was 8-58 years (means ± SE 4 2 ± 3, n = 20). Pancreases were processed, and fractions were enriched for endocrine cells to be used in transplantation. Samples of the endocrine cell fractions (50% endocrine cells as determined by electron microscopy) were used as control samples. The exocrine cell preparation immediately after isolation was designated as the exocrine cell fraction because it consisted of 55-65% acinar cells, 30-40% cytokeratin 19 (CK19) duct cells, and 2% endocrine cells. All preparations were cultured in suspension in Ham's F10, 1% bovine serum albumin (BSA) (Boehringer Mannheim, Mannheim, Germany), 7.5 mmol/l glucose, 50 µg/ml streptomycin, 50 U/ml penicillin, and 2 mmol/l L-glutamine at 37°C in a humidified atmosphere of 5% CO 2 . Every other day, the medium was renewed. During the first days of culture, a marked loss of acinar cells was evident, as judged by measuring the DNA content (of surviving cells) and by cell type identification (of disintegrating cells) with electron microscopy. After 4 days of culture, this fraction was designated as "duct cells" because it consisted of >90% CK19 + duct cells and 5% endocrine cells. In one set of experiments, samples of cultured endocrineenriched cell preparations were dissociated and were further separated into endocrine and nonendocrine cells (21).
Ipf-1 EXPRESSION IN ADULT HUMAN PANCREAS
For metabolic labeling of phosphorylated protein, cells were preincubated for 2 h at 37°C in phosphate-free RPMI in the presence of 0.1% BSA, followed by the addition of [ 3 2 P]-labeled orthophosphate (0.5 mCi 3 2 P i /1 1 0 6 cells) (Amersham, Buckinghamshire, U.K.) and further incubation for 4 h. HeLa cells were provided by Dr. B. Rombaut, Department of Microbiology, Vr i j e Universiteit Brussel, and MIN6 cells were cultured as described by Ishihara et al. (22) . Immunohistochemical and immunocytochemical analysis. I m m u n o h i s t ochemical analysis was performed on paraffin sections (3 µm thick) by using the streptavidin-biotin-peroxidase method, the alkaline phosphatase streptavidinbiotin complex (ABC) method (20), or indirect immunofluorescence. Similar methods were applied to cells from suspension cultures after overnight fix a t i o n in 4% buffered formaldehyde and pelleting in 2% agarose before paraffin embedding. Before incubation with the first antibody, sections for Ipf-1 staining were microwave treated and those for CK19 staining were trypsin treated. Sections of human adult pancreases from 18 donors were analyzed for Ipf-1 expression with an antiserum directed against the first 75 amino acids of Xenopus leavis h o m e obox 8 (XIHbox8) expressed as a glutathione S-transferase fusion protein. The aminoterminal region of XIHbox8 has a transactivating function and is conserved in mammalian Ipf-1 (23-25). Ipf-1 antiserum was used at a 1:1,000 dilution. Mouse monoclonal antibodies carbohydrate antigen 19-9 (CA19-9) (Biomed, Fullerton, CA) and CK19 (Dako, Santa Barbara, CA) directed against duct cell-specific markers were 50-and 20-fold diluted, respectively. Protein extraction, immunoblotting, and immunoprecipitation assay. Samples for immunoblotting of total cellular protein were washed twice in phosphate-buffered saline (PBS) followed by homogenization and solubilization in 5 0 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 1% Nonidet P40, 0.1% SDS, 1% deoxycholate, and 2 mmol/l EDTA containing a mixture of proteinase (1 mg leupeptin, 1 mg antipain, 10 mg benzamidine, and 5 mg trypsin inhibitor per ml apoprotinin; 1 mg chymostatin; 1 mg pepstatin A; and 0.5 mol/l phenylmethylsulfonyl flu or i d e / 1 ml DMSO) and phosphatase inhibitors (10 mmol/l sodium vanadate, 5 0 mmol/l NaF, 1 mmol/l sodium pyrophosphate, 10 mmol/l -g l y c e r o p h o s p h a t e , 1 0 mmol/l p-nitrophenyl phosphate). Extracts were cleared by centrifugation, and protein concentration was determined by using a colorimetric assay involving bicinchoninic acid (Pierce, Rockford, IL). Nuclear proteins were separated from cytoplasmic proteins as described by Macfarlane et al. (14) .
Immunoprecipitation of Ipf-1 from 100 to 200 µg of RIPA-extracted protein was done by overnight rotation at 4°C in the presence of 2 µl anti-Ipf-1 followed by a 1-h incubation with 25 µl of protein A sepharose beads. Immunocomplexes were pelleted, and beads were resuspended before 3 min of boiling in sample buffer ( 0 . 5 mol/l Tris [pH 6.8], 2% SDS, 10% glycerol, bromophenol blue, and 20 m m o l / l dithiothreitol or 10% -m e r c a p t o e t h a n o l ) .
Protein extracts (5-25 µg) were separated on a 10% SDS-PAGE together with the Benchmark molecular weight marker (Life Technologies, Rockville, MD). Nonradioactive samples were electroblotted to nitrocellulose (Protran; Schleicher and Schuell, Keene, NH). Blots were incubated for 1 h at room temperature in 5% dry milk/PBS and overnight at 4°C with anti-Ipf-1 serum (1/2,000) (23) (24) (25) . A different polyclonal Ipf-1 antiserum (antibody 1859) raised against a glutathione-S-transferase (GST)/Ipf-1 fusion protein containing the 63 COOH-terminal amino acids of rat Ipf-1 (26) was used to confirm signal specific i t y. Signals were detected by using horseradish peroxidase-coupled secondary antibody and enhanced chemiluminescence (Amersham, U.K.). Gels containing radioactive samples (total protein and Ipf-1 immunoprecipitates from [ 3 2
P i ]-labeled cells) were fixed in acetic acid/methanol (10%/25%), rehydrated, dried, and exposed to autoradiographic fil m s . Electrophoretic mobility shift assay. Nuclear extracts (0.5 µg protein) were incubated at 4°C for 20 min in 10 mmol/l HEPES (pH 7.9), 50 mmol/l KCl, 5 m m o l / l M g C l 2 , 0.05 mmol/l EDTA, 0.5 mmol/l dithiothreitol, and 10% glycerol in the presence and absence of Ipf-1 antiserum or competitor oligonucleotides, followed by addition of a [ 3 2 P]-labeled oligonucleotide with an A3 target sequence and further incubation at 4°C for 20 min. Protein complexes were separated by electrophoresis on a 4% nondenaturing polyacrylamide gel at 4°C. Data analysis. The optical density of the signals on films that underwent minimal exposure times was measured by using NIH Image 1.60 software (National Institutes of Health, Bethesda, MD). Data are means ± SE for the number of experiments stated. Statistical significance of the differences between experimental groups was assessed by using the unpaired two-tailed Student's t t e s t .
R E S U LT S
In situ expression of Ipf-1 in the adult human pancreas. Sections of adult human pancreases were analyzed for Ipf-1 by using immunocytochemistry. Most islet -cells express Ipf-1 (Fig. 1A) . Immunoreactivity for Ipf-1 was also located in the nuclei of cells lining small intralobular ducts as well as in scattered cells in numerous acini. About one-third of all cells in the exocrine lobules immunoreacted with anti-Ipf-1 ( F i g . 1A), which corresponds with the frequency of centroacinar cells and duct cells in the human pancreas (20). Double immunostaining for Ipf-1 and the ductal marker syalyl-L e w i s a (CA19-9) (20) indicated that 95% of duct cells express Ipf-1 (Fig. 1B) . Most Ipf-1 immunostaining in duct and endocrine cells was blocked by Ipf-1 peptide. This blocking did not alter the very weak signal in acinar cells, which was therefore considered to be nonspecific (data not shown). An identical pattern of Ipf-1 expression was observed when tissue was analyzed after biopsy of adult human pancreases (data not shown). Expression of Ipf-1 in the exocrine and endocrine cell fractions immediately after isolation. Human pancreases were collagenase digested and dispersed into cell aggregates that were enriched for endocrine (>50% endocrine cells) or exocrine (>95% exocrine cells) cells. On the day of isolation, the exocrine fraction consisted of 55-65% acinar cells and 30-40% CK19 + duct cells (Fig. 1D ). Of these exocrine cells, 30-40% expressed Ipf-1 (Fig. 1C) . At least four proteins with molecular weights of 30, 42, 45, and 50 kDa (p30, p42, p45, and p50) were recognized by Ipf-1 antiserum on immunoblots of proteins extracted from endocrine or exocrine cells when analyzed immediately after isolation ( Fig. 2A) . The four bands were Ipf-1 specific because preadsorption of the antibody by an excess of antigenic peptide prevented immunostaining of the protein blots by Ipf-1 antibody (Fig. 2C) . Moreover, the same results were obtained by using a different antiserum raised against the COOH-terminal part of the homeodomain region (26) (data not shown). When normalized to p42 intensity in endocrine cells, the relative abundance was 7:100:40:2 for p30:p42:p45:p50 in endocrine cells and 1:5:2:1 in exocrine cells ( Fig. 2A and B) . In the freshly isolated exocrine cell fraction, p42 and p45 were thus expressed at about a 20-fold lower abundance compared with the endocrine cell fraction ( F i g . 2A and B). The levels of p30 and p50 were generally low and variable. Expression of Ipf-1 in cultured exocrine and endocrine cell fractions. In the endocrine cell fraction, the abundance of p30, p42, and p45 was not greatly affected by 4 days of culture when normalized to p42 abundance in freshly isolated endocrine cells, but their p50 level varied with culture (7:110:41:10) ( Fig. 3A and D) . In the exocrine cell fraction, the abundance of all four Ipf-1 proteins increased with culture ( F i g . 3B); after 4 days, the relative abundance of p30, p42, p45 and p50 was 7:60:18:35 ( Fig. 3C and D) , and the sum of the band intensities was 70% of that in the endocrine cell fraction. Thus, the levels of p42 and p45 in the cultured exocrine cell fraction were only 2-fold lower than those in the cultured endocrine cell fraction and were 10-fold higher than those in the exocrine cell fraction immediately after isolation (Figs. 2B and 3D ). This latter increase is due to the fact that most acinar cells disappear during culture of the exocrine cell fraction. The remaining cells are 90% positive for the duct cell markers CK19 (Fig. 1F ) or CA19-9 (Fig. 1H ) and are therefore identified as duct cells, of which 95% expressed Ipf-1 (Fig. 1E and G) . Most, if not all, duct cells coexpress Ipf-1 and CA19-9, as shown by double immunostaining for both proteins ( Fig. 1G and H) .
These results indirectly indicate that the Ipf-1 signal in the freshly isolated exocrine cell fraction originates from its composing duct cells, which represent one-third of this fraction and are eightfold smaller than the acinar cells.
Therefore, the relative contribution of duct cells will be markedly diluted on immunoblots that contain equal amounts of total cellular protein from the freshly isolated exocrine cell fraction compared with a 4-day cultured exocrine cell fraction.
We can, on the other hand, exclude the possibility that contaminating duct cells are responsible for the measured p42 and/or p45 content in the endocrine-enriched fraction. Both proteins were indeed strongly expressed in purified -c e l l preparations (>80% insulin-positive cells) that were obtained after fluorescence-activated cell sorting (FACS) of dissociated endocrine-enriched fractions (Fig. 3E) . Phosphorylation of Ipf-1 in duct and endocrine cells. Nuclear translocation and protein phosphorylation have been proposed to regulate the transactivating potential of Ipf-1 (13,14,16). To find out whether duct cell Ipf-1 was translocated to the appropriate subcellular compartment and properly modified, we investigated its presence in the nucleus and its phosphorylation status. Duct nuclei contained most of p42 and p45, whereas p30 was present in duct cytoplasm ( Fig. 4A and B) . Also in endocrine cells, p42 and p45 were mainly found in the nuclear fraction (Fig. 4B) .
FIG. 1. Analysis of Ipf-1 immunoreactivity in adult human pancreas in situ (A and B) and in isolated duct cells (C, E, and G). Sections of adult donor pancreases (A and B) or of isolated exocrine cell fractions (C -H) were immunostained for Ipf-1 (A-C, E, and G) and/or the duct cell markers CA19-9 (B and H) or CK19 (D and F) as described in R E S E A R C H D E S I G N A N D M E T H O D S
The phosphorylation of Ipf-1 was analyzed after 4-h metabolic labeling with [ 3 2 P]orthophosphate. Ipf-1 was immunoprecipitated from protein homogenates of metabolically labeled cells and was subjected to gel electrophoresis and a u t o r a d i o g r a p h y. Specificity of Ipf-1 immunoprecipitation was confirmed on protein extracts from unlabeled cells. Ipf-1 immunoprecipitates were separated on polyacrylamide gels next to total protein extracts. In both lanes, 42-and 45-kDa bands appeared on Ipf-1 immunoblots (Fig. 4C) . Autoradiographs of Ipf-1 immunoprecipitates from [ 3 2 P ] o r t h o p h o sphate-labeled endocrine or duct cells revealed a 42-kDa phosphorylated protein in both cell preparations, whereas phosphorylated p45 was found only in endocrine cells (Fig. 4D,  middle panel) . The total amount of protein phosphorylation was similar in endocrine and duct cells (Fig. 4D, right panel) . The mouse -cell line MIN6 was used as a control and was found to phosphorylate only p42 within the 4-h labeling period; antibody blocking with the antigenic peptide removed this signal (Fig. 4D, left panel) . Although the absolute amounts of phosphorylation of p45 and p42 in endocrine cells were comparable, the relative amount of phosphorylation per molecule of p45 was twofold higher compared with p42. When identical amounts of total cellular protein were compared, the molecular phosphorylation of p42 was sevenfold higher in endocrine cells compared with duct cells. The actual amount of molecular phosphorylation may be higher in pure 
Samples were prepared and analyzed as described in R E S E A R C H D E S I G N A N D M E T H O D S. Four
Ipf-1 protein species were detected: p30, p42, p45, and p50. B: Abundance of Ipf-1 was determined by scanning the optical density (OD) of the Ipf-1 signals on immunoblots. Data from three independent donor pancreases are presented as means of optical density units ± SE. Endocrine p42 and p45 were more abundant (P < 0.01) than any other Ipf-1 species analyzed in this figure, and p42 was 2.5-fold more abundant than p45 in both the endocrine and exocrine cell fractions (P < 0.005; n = 3). C: Analysis of Ipf-1 antibody specificity. Ipf-1 antiserum was preincubated with the antigenic peptide for 1 h at room temperature before adding it to a protein blot containing extracts from endocrine, exocrine (acinar + duct), and duct cells prepared
as described in R E S E A R C H D E S I G N A N D M E T H O D S.
After development of the signal, the same blot was incubated with anti-Ipf-1 without peptide. Exposure times of the immunoblot were 5 min without peptide and 25 min with peptide.
A C B
endocrine cells because the endocrine enrichment of the endocrine cell preparations used for this part of the study was 70%. DNA binding by Ipf-1 in duct and endocrine cells. To investigate whether the differences in Ipf-1 phosphorylation in endocrine and duct cells affected its complex formation and possibly its transactivation potential, DNA binding properties of Ipf-1 were compared in nuclear extracts from human pancreatic endocrine and duct cells. The A3 c i s-element of the human insulin gene promoter, a prominent binding site for I p f-1 (13,15,26), was used as a target sequence in electrophoretic mobility shift assays. Nuclear extracts prepared from MIN6, a mouse -cell line, were used as a positive control. MIN6 cells express nuclear proteins that form four A3 binding complexes: C1, C2, C4, and C5 (Fig. 5) . Complexes C4 and C5 were also found in nuclear extracts from HeLa, a human cervical tumor cell line, and did not undergo a supershift after addition of anti-Ipf-1 serum Fig. 2 . Exocrine preparations were depleted of acinar cells after 4 days of culture and highly enriched for duct cells (90% CK positivity and 5% insulin positivity). C: The endocrine and exocrine cell fractions from two adult pancreas donors were kept in suspension culture, and samples were taken at day 4, immunoblotted for Ipf-1, and quantified as in Fig. 2 . D: Quantification of Ipf-1 expression in endocrine and exocrine (90% duct) protein extracts from three independent donor pancreases. Endocrine p42 was more abundant (P < 0.05) than any other Ipf-1 species analyzed in this figure. Duct cell p42 was more abundant (P < 0.05) than duct cell p30 and p45, but diff e r e n c e s between p50 and p42 or p45 were not statistically significant (P > 0. , which suggests that they contain a ubiquitous homeodomain binding protein that recognized the A3 site. Complex C2 in MIN6 cells was Ipf-1 specific, was most abundant, and had a high affinity for A3 as determined by supershift, band intensity, and competition, respectively, with cold A3 oligonucleotides. More than a 200-fold molar excess of cold competitor oligonucleotide was necessary to block the binding of A3 to C2. This binding was apparently strongly sequence specific because incubation with a cold oligo 1 containing one base pair mismatch (data not shown) or a cold oligo 2 containing two base pair mismatches (Fig. 5B) completely abolished its competitor capacity. The signal representing the complex C1 was Ipf-1 specific and was less abundant than C2. Complex C1 had a lower affinity for the A3 sequence and was less sequence specific than C2 (Fig. 5A) .
FIG. 3. Ipf-1 expression in cultured exocrine and endocrine (ENDO) cells from adult human pancreas. Endocrine (A) and exocrine (B) cell fractions were cultured in suspension as described in R E S E A R C H D E S I G N A N D M E T H O D S. Sampling was at the times indicated, and analysis of Ipf-1 expression was as in

05). OD, optical density. E: Ipf-1 expression in FACS-purified -cells and duct cells. Cells from the endocrine-enriched fraction of two different adult human pancreases were FACS sorted as described in R E S E A R C HD E S I G N
Nuclear extracts from human endocrine cells contained an I p f -1 -s p e c i fic complex (C3) that affected A3 gel retardation to a lesser extent than C1 or C2 (Fig. 5C ). More than a 2 0 0-fold molar excess of cold A3 competitor oligo was necessary to fully displace labeled A3 from C3, and one base pair mismatch in the competitor oligo abolished its blocking c a p a c i t y, which implies rather high-sequence specificity and affinity of endocrine-specific C3 for binding to A3 (Fig. 5C) . Supershift of the endocrine C3 complex was complete ( F i g . 5C). In nuclei from human duct cells, A3 binding protein complexes C1, C4, and C5 were expressed (Fig. 5C ). Duct cell C1 bound to A3 with low sequence specificity because extensive mismatches ( 3) were necessary to fully abolish competitor activity for binding to the A3 site (Fig. 5C ). As in MIN6 nuclei, the binding of C1 to A3 was weak because a 5 0-fold molar excess of cold A3 oligo completely removed the DNA binding signal. The ductal C1 complex was only partly supershifted (±50%) when the nuclear extract was incubated with anti-Ipf-1 serum (Fig. 5C and D) . Identical results were obtained by analyzing duct and endocrine nuclear extracts from three different adult donors.
D I S C U S S I O N
The homeodomain protein Ipf-1 is a prominent transcriptional regulator of pancreatic embryogenesis (9,10) and glu- Fig. 2 . The p30 is mainly present in the cytosol, and p42 and p45 are in the nuclear fraction. B: Analysis of the expression of p42 and p45 in cytosolic and nuclear fractions of endocrine and duct cells was as in A, except that 10 µg of nuclear (NUCL) protein and 40 µg of cytoplasmic (CYTO) protein were applied on gel. C: Validation of immunoprecipitation of Ipf-1 from duct cells. Protein extracts were prepared and immunoblotted for Ipf-1 as in Fig. 2 without (ib, 25 µg 
FIG. 4. Phosphorylation of Ipf-1 in endocrine (ENDO) and duct cells of adult human pancreases. A: Subcellular localization of Ipf-1 protein species in duct cells. Cytosolic (CY) and nuclear (NU) fractions were prepared as described in R E S E A R C H D E S I G N A N D M E T H O D S, and 25 µg protein was immunoblotted as in
A B C D
cose responsiveness (13-16). Besides its major role in driving the ontogenesis of the endocrine pancreas, Ipf-1 may also be essential for neogenesis of adult endocrine cells. Endocrine neogenesis includes differentiation of precursor cells that likely reside among the cells lining the pancreatic duct (3,4). According to most previous investigations, Ipf-1 protein is not expressed in the exocrine cells of the normal adult rodent pancreas, although it is clearly present in islet cells (5, 27, 28) . In a recent study on regenerating rodent pancreases, Sharma et al. (19) found that duct cells contain I p f-1 transcripts, albeit at 10-fold lower levels than islets, and weakly express Ipf-1 protein. In preliminary experiments, we detected Ipf-1 by using immunocytochemical and immunoblot analysis of duct cells in the normal adult rat pancreas, but at lower levels than in islet cells (data not shown). Although we were unable to detect Ipf-1 expression in rat acinar cells (data not shown), others found low expression in some acini of mice pancreases by using the -galactosidase transgene as a reporter for Ipf-1 promoter activity (29) and showed that Ipf-1 is part of a transcriptional complex binding the elastase gene promoter (30). In adult human pancreatic cells, we observed the presence of Ipf-1 in islet cells and in duct cells but not in acinar cells. Because adult ducts are assumed to be the site for -c e l l neogenesis in humans, we systematically analyzed Ipf-1 in adult human duct cells.
In both duct and endocrine cells of the human pancreas, four Ipf-1 immunoreactive bands were identified, of 30, 42, 45, and 50 kDa each (p30, p42, p45, and p50, respectively). Analysis of purified human -cells (>80% purity) strongly suggests that all four Ipf-1 protein species were present in insulinexpressing cells. Both in duct cells and in -cells, p42 was the most abundant species, and p45 had a twofold lower expression than p42. In duct cells, expression of p50 was comparable with that of p45, whereas expression of p50 was variably low in endocrine cells; p30 was low in both cell types. The I p f-1 proteins p45 and p50 have not yet been described in other studies. The p30 protein likely corresponds to the cytosolic unphosphorylated form of p42 (13).
Only the p42 protein was phosphorylated in duct cells, whereas both the p42 and p45 proteins were phosphorylated in the endocrine cells. The apparent lack of phospho-p45 in duct cells may be caused by slower endogenous (de)phosphorylation kinetics compared with endocrine cells. Ipf-1 phosphorylation is known to be induced by increasing the glucose concentration from 3 to 20 mmol/l and by activating signaling through stress-activated protein kinase-2 (13). Both duct and endocrine cells were cultured at 7.5 mmol/l glucose, which is known to stimulate adult human -cells (21). Differences in glucose recognition and signaling in endocrine and duct cells may thus be responsible for the described differences in Ipf-1 phosphorylation. The signals controlling Ipf-1 expression and/or activity may conceivably be similar to those that regulate the cellular status of differentiation.
Phosphorylation of Ipf-1 in the cytoplasm has been proposed as a permissive event for translocation of Ipf-1 to the nucleus (14). We found Ipf-1 p30 located in the cytosol and the other Ipf-1 proteins in the nuclear fraction of both endocrine and duct cells. Ipf-1 is known to bind to the A3 recognition site of the promoter region of several -c e l l -s p e c i fic genes (2). Endocrine cells specifically expressed an Ipf-1 -c o n t a i n i n g complex (C3) that differs from the complexes found in duct cells or in the rodent -cell line MIN6. The sequence specific i t y and the affinity of C3 for A3 in endocrine cells were high compared with that of C1 in MIN6 or duct cells. Apart from the elastase promoter in acinar cells (30), no Ipf-1 target genes have so far been described in cells other than -cells. We found that nuclear extracts from duct cells contained a protein complex that recognized the A3 c is-element and that migrated in gel similar to C1, which is the least abundant of two Ipf-1-containing complexes in MIN6 cells. The supershift of C1 by anti-Ipf-1 in duct cells was not complete, which may be because of duct cell-specific masking of an epitope.
Endocrine cells contained twice as many phosphorylated residues per molecule of p45 as phospho-p42, which may, at least in part, explain its lower gel mobility. However, no clear correlation is evident between the status of Ipf-1 phosphorylation and the formation of DNA binding complexes in the two cell types described herein. Duct cells mainly contained phospho-p42 and the C1 DNA binding complex, whereas endocrine cells had higher amounts of both phospho-p42 and phospho-p45 but only one DNA binding complex (C3). Considering that phosphorylation may control both the DNA binding capacity of Ipf-1 and its transactivating potential (13,16) and that Ipf-1 acts as an elementary switch for gene expression, the differential phosphorylation of Ipf-1 in duct and endocrine cells may contribute to the regulation of differential gene expression in both cell types. Thus, phosphorylated p42 may bind to DNA as part of the same complex as p45, but only the latter may be transcriptionally active. Altern a t i v e l y, both phospho-Ipf-1 forms may belong to different protein complexes, which would eventually influence the promoter regions of different genes. The presence of p50, predominantly in duct cell nuclei, may help to regulate the formation of these protein complexes. This model implies that different Ipf-1 protein complexes assemble in endocrine and duct cells to determine the final cell type-specific transcriptional activities of Ipf-1. An analogous situation was found in rodent acini and -cell lines, in which different Ipf-1-containing transcription factor complexes control gene expression from either the elastase or the insulin gene promoter (30). The availability of duct cells may allow us to trace target genes of Ipf-1 in duct cells and consequently to investigate the function of Ipf-1 in this cell type.
Division of adult -cells is usually considered to be a rare event (4). However, a recent study on isolated human islet cells allocated a strong mitotic activity to the -cells in view of the Ipf-1 positivity of dividing cells (31). The present observations suggest that these Ipf-1 + cells may correspond to duct cells that are known to be abundantly present in human islet preparations and that are known to be responsive to mitogenic stimuli (32). We found 95% of duct cells to be positive for Ipf-1 protein. However, whether all these cells share the same precursor capacity or whether a duct cell subpopulation with stem cell characteristics exists is unknown. Functional heterogeneity among the -cells has been described in rat (33,34) and human pancreases (22) but has not yet been demonstrated in duct cells. Conceivably, duct cells that are closely located to endocrine cells may exhibit another phosphorylation status and be part of another transcriptionally active protein complex versus those that are associated with acinar cells. Different duct cell subpopulations may then differ in their precursor capacity. Understanding the mechanisms controlling gene expression and
